Therapeutic Human Monoclonal Antibodies Against Cancer
作者： Jamie Jarboe , Anumeha Gupta , Wasif Saif
DOI: 10.1007/978-1-62703-586-6_4
关键词: Trastuzumab 、 Cancer 、 Antibody 、 Monoclonal 、 Macular degeneration 、 Cancer research 、 Rituximab 、 Bevacizumab 、 Monoclonal antibody 、 Medicine
摘要: There are over 30 monoclonal antibodies that FDA approved for a variety of diseases ranging from malignancies to autoimmune macular degeneration. These include murine, fully humanized, and chimeric antibodies. number used in the treatment malignancies; fact, three top five grossing (bevacizumab, trastuzumab, rituximab) oncology Scolnik (mAbs 1:179-184, 2009).
springer.com
sci-hub.st 参考文章(47)
Michael Tomblyn, Radioimmunotherapy for B-cell non-hodgkin lymphomas. Cancer Control. ,vol. 19, pp. 196- 203 ,(2012) , 10.1177/107327481201900304
Peter F Bross, Julie Beitz, Gang Chen, Xiao Hong Chen, Eric Duffy, Lydia Kieffer, Sandip Roy, Rajeshwari Sridhara, Atiqur Rahman, Grant Williams, Richard Pazdur, None, Approval Summary: Gemtuzumab Ozogamicin in Relapsed Acute Myeloid Leukemia Clinical Cancer Research. ,vol. 7, pp. 1490- 1496 ,(2001)
A Osterborg, M J Dyer, D Bunjes, G A Pangalis, Y Bastion, D Catovsky, H Mellstedt, Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. ,vol. 15, pp. 1567- 1574 ,(1997) , 10.1200/JCO.1997.15.4.1567
K Jin Kim, Bing Li, Jane Winer, Mark Armanini, Nancy Gillett, Heidi S Phillips, Napoleone Ferrara, None, Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo Nature. ,vol. 362, pp. 841- 844 ,(1993) , 10.1038/362841A0
Mark D. Pegram, Giovanni Pauletti, Dennis J. Slamon, Her-2/neu as a Predictive Marker of Response to Breast Cancer Therapy Breast Cancer Research and Treatment. ,vol. 52, pp. 65- 77 ,(1998) , 10.1023/A:1006111117877
Nancy E. Hynes, Heidi A. Lane, ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Reviews Cancer. ,vol. 5, pp. 341- 354 ,(2005) , 10.1038/NRC1609
Lorenzo Galluzzi, Erika Vacchelli, Wolf Hervé Fridman, Jerome Galon, Catherine Sautès-Fridman, Eric Tartour, Jessica Zucman-Rossi, Laurence Zitvogel, Guido Kroemer, Trial Watch: Monoclonal Antibodies in Cancer Therapy OncoImmunology. ,vol. 2, pp. 28- 37 ,(2012) , 10.4161/ONCI.1.1.17938
Lutz Riechmann, Michael Clark, Herman Waldmann, Greg Winter, Reshaping human antibodies for therapy. Nature. ,vol. 332, pp. 323- 327 ,(1988) , 10.1038/332323A0
Fairooz Kabbinavar, Herbert I. Hurwitz, Louis Fehrenbacher, Neal J. Meropol, William F. Novotny, Grazyna Lieberman, Susan Griffing, Emily Bergsland, Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 21, pp. 60- 65 ,(2003) , 10.1200/JCO.2003.10.066
Kathryn Chapman, Nick Pullen, Lee Coney, Maggie Dempster, Laura Andrews, Jeffrey Bajramovic, Paul Baldrick, Lorrene Buckley, Abby Jacobs, Geoff Hale, Colin Green, Ian Ragan, Vicky Robinson, Preclinical development of monoclonal antibodies: considerations for the use of non-human primates. mAbs. ,vol. 1, pp. 505- 516 ,(2009) , 10.4161/MABS.1.5.9676